GSK plc has submitted a request to the FDA on July 14, 2025, to expand the use of its RSV vaccine, Arexvy, for adults aged 18-49 at increased risk, which could benefit over 21 million adults in the US with risk factors for severe RSV infection. A decision from the FDA is expected in the first half of 2026.